Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Impact of age on treatment outcomes in B-cell ALL

Mark Litzow • 6 Sep 2024
SOHO 2024
Acute Lymphoblastic Leukemia Leukemia Antibodies Dasatinib Inotuzumab ozogamicin Mercaptopurine

Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a study comparing the responses of acute lymphoblastic leukemia (ALL) B-cell samples from children and adults to various drugs. The research revealed differences in responses for seven of the drugs, which could be explained by differences in molecular subtypes. One drug showed greater benefits in children, potentially explaining their generally better outcomes. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Litzow

A trial investigating the addition of blinatumomab to consolidation chemotherapy in Ph- ALL 3:35
A trial investigating the addition of blinatumomab to consolidation chemotherapy in Ph- ALL
Mark Litzow • 6 Sep 2024
The incorporation of immunotherapy into frontline ALL treatment 2:00
The incorporation of immunotherapy into frontline ALL treatment
Mark Litzow • 6 Sep 2024
The future of frontline treatment in ALL: immunotherapy 1:36
The future of frontline treatment in ALL: immunotherapy
Mark Litzow • 27 Feb 2024
The advantage of early blinatumomab treatment over chemotherapy in ALL 2:15
The advantage of early blinatumomab treatment over chemotherapy in ALL
Mark Litzow • 27 Feb 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals